Onderneming PhaseBio Pharmaceuticals, Inc.
Aandelen
PHAS.Q
US7172241090
Biotechnologie & Medisch Onderzoek
slotkoers
Andere beurzen
|
Variatie 5 dagen | Verschil t.o.v. 1 jan (%) | ||
0,000001 USD | 0,00% | 0,00% | 0,00% |
Vakgebied
Aantal werknemers: 60
Verkoop per activiteit
USD in miljoen | 2020 | Gewicht | 2021 | Gewicht | Delta |
---|---|---|---|---|---|
Novel Therapies
100,0
%
| 0 | 100,0 % | 11 | 100,0 % | +3.284,69% |
Verkoop per regio
USD in miljoen | 2020 | Gewicht | 2021 | Gewicht | Delta |
---|---|---|---|---|---|
United States
100,0
%
| 0 | 100,0 % | 11 | 100,0 % | +3.284,69% |
Managers
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Jonathan Mow
CEO | Chief Executive Officer | 59 | 04-12-12 |
Lawrence Perkins
DFI | Director of Finance/CFO | 47 | 01-10-22 |
John Lee
CTO | Chief Tech/Sci/R&D Officer | 56 | 18-04-16 |
Susan Arnold
CTO | Chief Tech/Sci/R&D Officer | 49 | 01-10-10 |
General Counsel | 52 | 01-10-19 |
Besturend
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Edmund Harrigan
BRD | Director/Board Member | 71 | 13-12-18 |
Jonathan Mow
CEO | Chief Executive Officer | 59 | 04-12-12 |
Director/Board Member | 57 | 14-09-21 | |
Nancy Hutson
BRD | Director/Board Member | 74 | 05-03-18 |
Clay Thorp
FOU | Founder | 55 | 10-01-02 |
Director/Board Member | 57 | 27-02-19 | |
Alex Sapir
BRD | Director/Board Member | 57 | 12-02-20 |
Aandelenklasse
Stemming | Aantal | Vrij verhandelbaar | Bedrijfseigen aandelen | Drijvend Totaal | |
---|---|---|---|---|---|
Aandeel A | 1 | 49 888 083 | 49 767 625 ( 99,76 %) | 29 967 ( 0,0601 %) | 99,76 % |
Bedrijfsgegevens
PhaseBio Pharmaceuticals, Inc.
3500 South Dupont Highway Kent County
19901, Dover
+610 981 6500
http://www.phasebio.comSector
Vaira. 1 jan. | Kapi. | |
---|---|---|
0,00% | 49 | |
-2,31% | 103 mld. | |
+0,56% | 95,28 mld. | |
+1,69% | 22,15 mld. | |
-17,37% | 21,02 mld. | |
-9,30% | 18,15 mld. | |
-41,01% | 16,73 mld. | |
-14,85% | 16,05 mld. | |
+3,21% | 13,68 mld. | |
+33,54% | 12,17 mld. |
- Beurs
- Aandelen
- Koers PHAS.Q
- Onderneming PhaseBio Pharmaceuticals, Inc.